Active BE 0760.552.551Private limited company

MEGA PHARMA

Spiegellaan 63 ·1785 Merchtem, Belgium· 5 yrs active

Sector: Retail trade (47730)

Conclusion Checked

The computed 12-month bankruptcy probability of MEGA PHARMA is 1.9% (moderate). The 2025 annual accounts show equity of €108k and a net result of €-2k. Equity is growing by ~33.1% per year across the filed fiscal years. Its solvency ranks better than 85% of 1382 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 4 annual accounts.

Key figures

Equity	€108k
Net result	€-2k
Better than sector	85%
Active	5 yrs

Snowflake analysis 5 axes · computed by Checked

62 / 100

Strong profile, led by solvency.

Health 62

Profitability 0

Solvency 100

Growth 52

Stability 94

Bankruptcy probability (12 mo) Checked model v1 · free

1.9% Moderate

0%0,5%1,5%4%10%≥25%

Young company +Higher-failure-rate sector +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based

0 / 100

Low risk

Trust signals 3 signals

More than 3 years active

Founded in 2020, past the statistically most fragile first 3 years.

No legal incidents

No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.

Administratively compliant

No FOD Economie strikeouts (UBO, accounts, address, activity).

Administrative Flags 0 events

No administrative flags

Health barometer FY 2025 · computed

62 / 100 Healthy

050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →

Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.

Financial overview4 NBB filings

Annual accounts filed on 21-01-2026 with the NBB · fiscal year 2025 · micro

Operating resultNet result

Trajectory (indicative)

Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.

growing Equity: growth of ~33.1%/year over 4 fiscal years, indicative, assuming unchanged policy.

Solid line = filed figures · dashed = extended trend · area = indicative range.

How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison

Fiscal year 2025 · NACE 47, Retail trade · compared within the same schema type (micro schema)

Metric	This company	Sector median	Position in the sector
Solvency	71.8%	23.3%	better than 85% of 1382 sector peers
Net result	€-2k	€8k	better than 26% of 1380 sector peers
Equity	€108k	€26k	better than 80% of 1383 sector peers
Gross operating margin	€-2k	€36k	better than 13% of 1377 sector peers
Total assets	€150k	€133k	better than 54% of 1383 sector peers

Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.

Net profit

€-2k

- far below sector median

Total assets

€150k

+16.3% -63% vs sector

Equity

€108k

-1.9% -26% vs sector

Working capital

€108k

-1.9% -3% vs sector

Income taxes

€2

-99.9% -100% vs sector

Debt

€42k

+120.1% -83% vs sector

Debt ≤ 1y

€42k

+120.1% -83% vs sector

Current ratio

3.55

-47.2% +130% vs sector

Quick ratio

3.43

-48.8% +228% vs sector

Solvency

71.8%

-15.6% +99% vs sector

Debt / equity

0.39

+124.4% -78% vs sector

ROE

-1.9%

- far below sector median

ROA

-1.4%

- far below sector median

Figures by fiscal year

Highlight YoY changes (±10%)

Fiscal year	2025
Revenue	-
EBITDA	-
Net profit	€-2k
Cash flow	-
Staff costs	-
Income taxes	€2
Dividends	-
Total assets	€150k
Equity	€108k
Debt	€42k
of which ≤ 1y	€42k
of which > 1y	-
Working capital	€108k
Employees (FTE)	-

Ratios (computed)

	2025
Current ratio	3.55
Quick ratio	3.43
Working capital ratio	71.8%
Solvency	71.8%
Debt / equity	0.39
Long-term debt ratio	-
Interest coverage	-
Gross margin	-
Net margin	-
ROA	-1.4%
ROE	-1.9%
EBITDA margin	-
Days sales outstanding	-
Days payable outstanding	-
Inventory turnover	-
Days inventory (DSI)	-

Balance-sheet composition 2025

Equity & liabilities

Equity €108k · 71.8% Debt €42k · 28.2%

Full annual accounts

Filed balance sheet and income statement, exactly as deposited with the NBB.

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€150k
Current assets	29/58	€150k
Stocks & contracts in progress	3	€5k
Amounts receivable within one year	40/41	€95k
Cash & bank	54/58	€50k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€150k
Equity	10/15	€108k
Contributions / capital	10/11	€100k
Accumulated profits (losses)	14	€8k
Amounts payable	17/49	€42k
Amounts payable within one year	42/48	€42k
Trade debts payable within one year	44	€29k
Income statement
Gross operating margin	9900	€-2k
Operating result	9901	€-2k
Financial income	75	€258
Financial charges	65	€181
Result before taxes	9903	€-2k
Income taxes	67/77	€2
Net result for the period	9904	€-2k
Result to be appropriated	9905	€-2k

You're seeing the latest fiscal year only. Unlock 3 prior years (figures + ratios) with a paid plan. See plans →

Ratios computed by Checked.

Legal Structure

NACE primary	Retail trade(47730)
Legal form	Private limited company(610)
Incorporation	24-12-2020
Status	Active
Postal code	1785

Establishment units 1 location

MEGA PHARMA

Spiegellaan 63, 1785 MerchtemVervaardiging van werkkleding

since 20202.312.008.163

Physical sites registered in the Crossroads Bank for Enterprises (CBE).

Real-estate footprint Source: CBE × cadastre

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
23602H0246/00S002	Flanders	304 m²	1 · 162 m²	10.7 m · 2 fl.

Methodology

via registered seat: 1

1 of 1 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Updates 5 events

A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2026

21-01-2026

NBB filing Annual accounts filed

fiscal year 2025 · micro

2025

30-01-2025

NBB filing Annual accounts filed

fiscal year 2024 · micro

2024

31-01-2024

NBB filing Annual accounts filed

fiscal year 2023 · micro

2023

28-12-2023

State Gazette act Capital & shares

Anne Verhaeghe

31-01-2023

NBB filing Annual accounts filed

fiscal year 2022 · micro

Belgisch Staatsblad, acts 1 acts

Capital history · 1

28-12-2023

Capital change

All acts · 1 updated 2 years ago

2023

28-12-2023 Capital increase of €50,000 to €100,000 Capital & shares·Anne Verhaeghe

€50.000 → €100.000
Inbreng in geld · Apport en numéraire

Notary: Anne Verhaeghe · Meise

Original publication ↗

Technical details

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 100000.0,
      "delta_eur": 50000.0,
      "before_eur": 50000.0,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "POTOMS Kris",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": null,
          "n_shares_subscribed": 150,
          "contribution_amount_eur": null
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "STALLAERT Ann Marie-Germaine",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": null,
          "n_shares_subscribed": 150,
          "contribution_amount_eur": null
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "POTOMS Karen",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": null,
          "n_shares_subscribed": 50,
          "contribution_amount_eur": null
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "person",
          "name": "POTOMS Roger",
          "share_class": null,
          "liberation_pct": null,
          "contribution_kind": null,
          "n_shares_subscribed": 150,
          "contribution_amount_eur": null
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": 500,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 50000.0,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Anne Verhaeghe",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Meise",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2023-12-28",
    "filing_date": "2023-12-24",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2023-12-22",
    "unanimous": true,
    "under_authorized_capital": true,
    "underlying_resolution_date": "2023-12-22"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0760.552.551",
    "name_full": "MEGA PHARMA",
    "legal_form": "Besloten Vennootschap",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "uitgifte van het proces-verbaal van 22/12/2023",
    "lijst van de vennootschapsakten \u002B co\u00F6rdinatie van de statuten"
  ],
  "shareholders_after": [
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "POTOMS Kris",
      "role": null,
      "n_shares": 150,
      "share_class": null
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "STALLAERT Ann Marie-Germaine",
      "role": null,
      "n_shares": 150,
      "share_class": null
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "POTOMS Karen",
      "role": null,
      "n_shares": 50,
      "share_class": null
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "POTOMS Roger",
      "role": null,
      "n_shares": 150,
      "share_class": null
    }
  ],
  "share_classes_after": []
}

Credit advice verdict per customer and amount

AI due-diligence brief Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon

AI-generated from Checked data; indicative, not legal or investment advice.

Company registry (CBE) Crossroads Bank

Activities

Apotheken47730Detailhandel in farmaceutische producten47730Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden32500Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden32500Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels47740Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen47741Detailhandel in corrigerende brillen, lenzen en zonnebrillen47742Detailhandel in fotografische en optische artikelen en in precisieinstrumenten in gespecialiseerde winkels47782Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies70200Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering70220Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied72109Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied72190

Primary activity highlighted.

Names & trade names

Legal nameNL

MEGA PHARMA

Registered office

Spiegellaan 63

1785 Merchtem, Belgium

Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.

Similar companies Same NACE

Pharmacie Fennia BE 0406.552.833 · Brussel

Apotheek Pauwengraaf BE 0424.190.106 · Maasmechelen

Apotheek De Swaene BE 0426.501.080 · Brugge

APOTHEEK AMELOOT BE 0429.047.034 · Machelen (Brab.)

APOTHEEK FRANSEN BE 0428.233.422 · Zoersel